<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13080">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427921</url>
  </required_header>
  <id_info>
    <org_study_id>W06-405</org_study_id>
    <nct_id>NCT00427921</nct_id>
  </id_info>
  <brief_title>Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>A Multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To make adalimumab available to subjects suffering from moderately to severely active
      Crohn's Disease (CD) and to expand the safety information on adalimumab. The study also
      assessed changes in Patient Reported Outcome Measures from baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 3, multicenter, open-label, Early Access Study with an induction regimen of
      adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by
      maintenance dosing of 40 mg every other week (eow) starting at Week 4 in subjects with
      moderately to severely active Crohn's Disease (CD) who were eligible to receive biologic
      therapy or who had failed to respond to, lost response to, or were intolerant to infliximab.
      Failure of prior therapy was determined by the Investigator. Subjects were to have an 8-week
      wash-out period prior to Baseline from the last dose of infliximab.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Extent of Exposure - Duration in Days</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Injections of Adalimumab</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections.</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fistula Count Mean Change From Baseline (Change in Number of Fistulas From Baseline).</measure>
    <time_frame>Week 12, Week 24, and Last Assessment Value (last nonmissing value)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Health Care Resource Utilization</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Employment Status: Number of Subjects Employed</measure>
    <time_frame>Baseline, Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50% Improvement in Draining Fistula Count and Fistula Healing</measure>
    <time_frame>Week 12, Week 24, Last Assessment Value (last nonmissing value)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment - Change From Baseline in Overall Work Impairment</measure>
    <time_frame>Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology - Change From Baseline to Final Visit</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Chemistry - Change From Baseline to Final Visit</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis - Change From Baseline to Final Visit</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment - Change From Baseline in Absenteeism</measure>
    <time_frame>Weeks 4, 8, 12, and 24, and Last Assessmentl Value (last nonmissing value)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment - Change From Baseline in Presenteeism</measure>
    <time_frame>Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment - Change From Baseline in Activity Impairment</measure>
    <time_frame>Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>160 mg loading dose, 80 mg at week 2, 40 mg every other week</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ABT-D2E7</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 18 years of age and older

          -  Females: Not of childbearing potential OR Practicing approved birth control
             throughout the study and for 150 days after study completion

          -  Diagnosis of moderate to severe CD for greater than 16 weeks prior to screening;
             Crohn's Disease Activity Index score &gt; 220 OR Harvey Bradshaw Index equal to or
             higher than 7, and who are refractory to optimal conventional therapies such as,
             5-aminosalicylic acid (5-ASA), glucocorticoids, and immunosuppressive therapies
             (azathioprine, 6-MP and MTX)

          -  Subjects who failed prior infliximab therapy (as determined by the primary
             investigator), including those who never clinically responded (&quot;primary
             non-responders&quot;)

        Exclusion Criteria:

          -  History of cancer other than some skin and cervical cancers

          -  History of opportunistic infections, central nervous system (CNS) demyelinating
             disease, chronic viral hepatitis, or untreated tuberculosis

          -  Subjects with other, poorly controlled medical conditions

          -  Subjects with any prior exposure to TysabriÂ® (natalizumab)

          -  Subjects who have received any investigational agent in the past 30 days or 5
             half-lives prior to screening (whichever is longer)

          -  Female subjects who are pregnant or breast-feeding or considering becoming pregnant
             during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jimmy Baloukas</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Remo Panaccione, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Director, Inflammatory Bowel Disease Clinic, Associate Professor of Medicine, University of Calgary, Calgary, AB, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Global Medical Information - Abbott</name>
      <address>
        <city>Abbott Park</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.humira.com/</url>
    <description>For more information, see attached website</description>
  </link>
  <verification_date>November 2009</verification_date>
  <lastchanged_date>November 12, 2009</lastchanged_date>
  <firstreceived_date>January 26, 2007</firstreceived_date>
  <firstreceived_results_date>January 9, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Tom Koutsavlis, Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>40 mg Adalimumab Every Other Week</title>
          <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event + Hospitalization</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event + Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event + No Response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event + Worsening of CD</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event + No Therapeutic Benefit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event + Lost Response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event + Withdrawn from Study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent + Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>40 mg Adalimumab Every Other Week</title>
          <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="304"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="296"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="173"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="131"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="291"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="304"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Alcohol</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>User</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="147"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ex-User</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Non-User</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="142"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>C-Reactive protein mg/dL</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt; 1.0 mg/dL</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="148"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt; = 1.0 mg/dL</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="155"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Missing</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Nicotine</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>User</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="98"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ex-User</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="84"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Non-User</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="122"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Number Subjects With Draining Cutaneous Fistulas at Screening</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Count 0 lesions</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="235"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count 1 lesion</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count 2 lesions</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count 3 lesions</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count &gt;=4 lesions</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Missing</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Number Subjects with Perianal Fistulas at Screening</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Count 0</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="244"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count 1</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count 2</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count 3</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count &gt;=4</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Missing</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Number of Subjects with Abdominal Fistulas at Screening</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Count 0</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="291"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count 1</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count 2</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count 3</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Count &gt;=4</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Missing</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Summary of Locations of Crohn's Disease at Screening (All Treated Subjects)</title>
          <description>Crohn's Disease may be at multiple locations</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Anal/Perianal</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Gastroduodenum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Rectum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Jejunum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="54"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ileum + Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Jejunum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Rectum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Rectum + Ileum + Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Gastroduodenum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon + Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="64"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon + Ileum + Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon + Jejunum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon + Rectum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon + Rectum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon + Rectum + Ileum + Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon + Gastroduodenum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon+GD+Jejunum+Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon+GD+Rectum+ Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Colon+GD+Rectum+Jejunum+Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Ileum + Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Jejunum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Rectum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Rectum + Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Rectum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon + Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon + Ileum + Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon + Jejunum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon + Rectum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon + Rectum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon + Rectum + Ileum + Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon + Rectum +Jejunum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon + GD + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal + Colon + GD +Rectum + Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Anal/Perianal+Colon+GD+Rectum+Jejunum+Ileum</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight in kilograms</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt; = 70 kg</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="163"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt; 70 kg</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="141"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Duration of Crohn's Disease at Screening in Years</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11.8" spread="9.54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Extent of Exposure - Duration in Days</title>
        <description>Extent of exposure for all adalimumab treated subjects</description>
        <time_frame>Up to 24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>In addition to the Intent To Treat population, summaries for outcome measures were provided for the analyzable subsets, and subjects in the Per-Protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Extent of Exposure - Duration in Days</title>
            <description>Extent of exposure for all adalimumab treated subjects</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="159.2" spread="34.78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Harvey-Bradshaw Index (HBI) Mean Change From Baseline</title>
        <description>HBI score (range 0-30) sum subtotal of 5 parameters of subject's CD activity: a)Well being 0=very well-4=terrible b) Abdominal pain 0=none- 3=severe c) Number liquid stools per day d) Abdominal mass 0=none-3=tender e) Complications: 1 point each. Decrease indicates improvement. Absolute decrease of 3 units on scale is clinically important.</description>
        <time_frame>Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to Treat - subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Harvey-Bradshaw Index (HBI) Mean Change From Baseline</title>
            <description>HBI score (range 0-30) sum subtotal of 5 parameters of subject's CD activity: a)Well being 0=very well-4=terrible b) Abdominal pain 0=none- 3=severe c) Number liquid stools per day d) Abdominal mass 0=none-3=tender e) Complications: 1 point each. Decrease indicates improvement. Absolute decrease of 3 units on scale is clinically important.</description>
            <units>Units on scale</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.39" lower_limit="-4.94" upper_limit="-3.84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.53" spread="5.175" lower_limit="-5.12" upper_limit="-3.93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.32" spread="5.008" lower_limit="-5.90" upper_limit="-4.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.36" spread="5.031" lower_limit="-6.96" upper_limit="-5.75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Assessment Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.92" spread="5.162" lower_limit="-6.50" upper_limit="-5.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fistula Count Mean Change From Baseline (Change in Number of Fistulas From Baseline).</title>
        <description>Draining fistula counts is the sum of abdominal and perianal fistulas for each subject at each visit.</description>
        <time_frame>Week 12, Week 24, and Last Assessment Value (last nonmissing value)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Fistula Count Mean Change From Baseline (Change in Number of Fistulas From Baseline).</title>
            <description>Draining fistula counts is the sum of abdominal and perianal fistulas for each subject at each visit.</description>
            <units>number of fistulas</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.17" spread="0.644"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.15" spread="0.587"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Assessment Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.15" spread="0.567"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Injections of Adalimumab</title>
        <description>Extent of exposure for all adalimumab treated subjects</description>
        <time_frame>Up to 24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>In addition to the Intent To Treat population, summaries for outcome measures were provided for the analyzable subsets, and subjects in the Per-Protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Number of Injections of Adalimumab</title>
            <description>Extent of exposure for all adalimumab treated subjects</description>
            <units>injections</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Number of Injections During Induction Therapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" spread="0.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number of Injections During Maintenance Therapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.8" spread="4.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Compliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections.</title>
        <description>Treatment compliance (%) = 100 * (Number of doses of study medication actually received)/(Number of doses planned during the subject's participation in the study).</description>
        <time_frame>Up to 24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>In addition to the Intent To Treat population, summaries for outcome measures were provided for the analyzable subsets, and subjects in the Per-Protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Compliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections.</title>
            <description>Treatment compliance (%) = 100 * (Number of doses of study medication actually received)/(Number of doses planned during the subject's participation in the study).</description>
            <units>Percentage of injections</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98.85" spread="4.207"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Mean Change From Baseline</title>
        <description>Quality of life questionnaire for patients with IBD consisting of 4 domains: systemic, social, emotional, and bowel. This is a 10-item questionnaire, and all items are reported with a 7-point scale (ranging from 1 = poor HRQOL, to 7 = optimum HRQOL). Total SIBDQ score ranges from 10 (quality of life has been negatively affected tremendously by IBD) to 70 (quality of life is barely impacted by IBD). A change greater than 9 points was the minimal clinically important difference (MCID).</description>
        <time_frame>Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)</time_frame>
        <safety_issue>No</safety_issue>
        <population>In addition to the Intent To Treat population, summaries for outcome measures were provided for the analyzable subsets, and subjects in the Per-Protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Mean Change From Baseline</title>
            <description>Quality of life questionnaire for patients with IBD consisting of 4 domains: systemic, social, emotional, and bowel. This is a 10-item questionnaire, and all items are reported with a 7-point scale (ranging from 1 = poor HRQOL, to 7 = optimum HRQOL). Total SIBDQ score ranges from 10 (quality of life has been negatively affected tremendously by IBD) to 70 (quality of life is barely impacted by IBD). A change greater than 9 points was the minimal clinically important difference (MCID).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.16" spread="10.692"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.85" spread="11.591"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.14" spread="11.783"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.06" spread="12.209"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Assessment Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.74" spread="12.629"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Health Care Resource Utilization</title>
        <description>From the &quot;Overall Health Care Resource Utilization Questionnaire&quot;: Number visits to physician, number visits to Emergency Room, number of hospital admissions, number of days of hospitalization.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>In addition to the Intent To Treat population, summaries for outcome measures were provided for the analyzable subsets, and subjects in the Per-Protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Health Care Resource Utilization</title>
            <description>From the &quot;Overall Health Care Resource Utilization Questionnaire&quot;: Number visits to physician, number visits to Emergency Room, number of hospital admissions, number of days of hospitalization.</description>
            <units>number of visits</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Number of visits to a physician</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.13" spread="2.794"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number of visits to Emergency Room</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.17" spread="0.522"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number of hospital admissions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.10" spread="0.346"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number of days of hospitalizations</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.60" spread="2.790"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Employment Status: Number of Subjects Employed</title>
        <description>Summary of employment status of those employed.</description>
        <time_frame>Baseline, Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)</time_frame>
        <safety_issue>No</safety_issue>
        <population>In addition to the Intent To Treat population, summaries for outcome measures were provided for the analyzable subsets, and subjects in the Per-Protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Employment Status: Number of Subjects Employed</title>
            <description>Summary of employment status of those employed.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="195" spread="64.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="198"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="192"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Assessment Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="208"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>50% Improvement in Draining Fistula Count and Fistula Healing</title>
        <description>Decrease in draining fistula is beneficial. &quot;50 percent improvement&quot; refers to a reduction in the number of baseline fistula by 50 percent.</description>
        <time_frame>Week 12, Week 24, Last Assessment Value (last nonmissing value)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent To Treat</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>50% Improvement in Draining Fistula Count and Fistula Healing</title>
            <description>Decrease in draining fistula is beneficial. &quot;50 percent improvement&quot; refers to a reduction in the number of baseline fistula by 50 percent.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Week 12 50% Improvement in draining fistula</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24 50% Improvement in draining fistula</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Value 50% Improvement in draining fistula</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 Fistula Healing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24 Fistula Healing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Assessment Value Fistula Healing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Activity Impairment - Change From Baseline in Overall Work Impairment</title>
        <description>Scores are expressed as impairment percentages, higher numbers indicate greater impairment and less productivity (0% = no impairment; 100% = total loss of work productivity).
Minimal clinically important difference = 7 points. Measure is Mean percent change.</description>
        <time_frame>Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)</time_frame>
        <safety_issue>No</safety_issue>
        <population>In addition to the Intent To Treat population, summaries for outcome measures were provided for the analyzable subsets, and subjects in the Per-Protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Work Productivity and Activity Impairment - Change From Baseline in Overall Work Impairment</title>
            <description>Scores are expressed as impairment percentages, higher numbers indicate greater impairment and less productivity (0% = no impairment; 100% = total loss of work productivity).
Minimal clinically important difference = 7 points. Measure is Mean percent change.</description>
            <units>Units on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-22.08" spread="28.454"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-22.36" spread="29.337"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-29.93" spread="33.669"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-31.23" spread="30.403"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Assessment Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-28.49" spread="32.286"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematology - Change From Baseline to Final Visit</title>
        <description>Changes from the Group mean at baseline are compared to the final visit Group mean value</description>
        <time_frame>Up to 24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hematology - Change From Baseline to Final Visit</title>
            <description>Changes from the Group mean at baseline are compared to the final visit Group mean value</description>
            <units>number</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Hemoglobin (g/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.2" spread="12.43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematocrit (fraction)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.011" spread="0.0376"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red blood cell count (x10^9/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.03" spread="0.353"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet Count (x10^9/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-30.2" spread="89.28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White blood cell count (x10^9/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.59" spread="3.297"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neutrophils (x10^9/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.005" spread="3.1777"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lymphocytes (x10^9/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.408" spread="0.7285"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Monocytes (x10^9/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.014" spread="0.1725"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eosinophils (x10^9/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.009" spread="0.1505"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Basophils (x10^9/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.015" spread="0.0617"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Chemistry - Change From Baseline to Final Visit</title>
        <description>Changes from the Group mean at Baseline are compared to the final visit Group mean value</description>
        <time_frame>Up to 24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Chemistry - Change From Baseline to Final Visit</title>
            <description>Changes from the Group mean at Baseline are compared to the final visit Group mean value</description>
            <units>number</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>SGPT/ALT (U/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="17.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SGOT/ALT (U/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="10.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline phosphatase (U/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.2" spread="21.53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Bilirubin (mcmol/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="4.06"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine (mcmol/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7" spread="10.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN (mmol/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.06" spread="1.367"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Uric acid (mcmol/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.6" spread="52.38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Inorganic phosphate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.016" spread="0.2588"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium (mmol/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.008" spread="0.1189"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium (mmol/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.3" spread="2.38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium (mmol/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.00" spread="0.779"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin (G/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" spread="4.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total protein (G/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.8" spread="4.83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cholesterol (mmol/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.021" spread="0.7024"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides (mmol/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.093" spread="0.7581"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>C-reactive protein (mg/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.181" spread="28.7023"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose â fasting (mmol/L)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.268" spread="1.3893"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinalysis - Change From Baseline to Final Visit</title>
        <description>Changes from the Group mean at baseline are compared to the final visit Group mean value</description>
        <time_frame>Up to 24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Urinalysis - Change From Baseline to Final Visit</title>
            <description>Changes from the Group mean at baseline are compared to the final visit Group mean value</description>
            <units>number</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Urine pH</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.02" spread="0.980"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Specific gravity</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.0004" spread="0.00713"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Activity Impairment - Change From Baseline in Absenteeism</title>
        <description>The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.</description>
        <time_frame>Weeks 4, 8, 12, and 24, and Last Assessmentl Value (last nonmissing value)</time_frame>
        <safety_issue>No</safety_issue>
        <population>In addition to the Intent To Treat population, summaries for outcome measures were provided for the analyzable subsets, and subjects in the Per-Protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Work Productivity and Activity Impairment - Change From Baseline in Absenteeism</title>
            <description>The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.99" spread="24.592"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-7.55" spread="27.543"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.74" spread="33.477"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.54" spread="27.260"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Assessment Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.46" spread="29.167"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Activity Impairment - Change From Baseline in Presenteeism</title>
        <description>The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.</description>
        <time_frame>Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)</time_frame>
        <safety_issue>No</safety_issue>
        <population>In addition to the ITT population, summaries for outcome measures were provided for the analyzable subsets, and subjects in the Per-Protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Work Productivity and Activity Impairment - Change From Baseline in Presenteeism</title>
            <description>The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.</description>
            <units>Units on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-20.58" spread="26.115"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-19.94" spread="27.151"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-25.79" spread="30.113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-28.96" spread="28.472"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Assessment Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-26.69" spread="30.058"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Activity Impairment - Change From Baseline in Activity Impairment</title>
        <description>The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.</description>
        <time_frame>Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)</time_frame>
        <safety_issue>No</safety_issue>
        <population>In addition to the Intent To Treat population, summaries for outcome measures were provided for the analyzable subsets, and subjects in the Per-Protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg Adalimumab Every Other Week</title>
            <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Work Productivity and Activity Impairment - Change From Baseline in Activity Impairment</title>
            <description>The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.</description>
            <units>Units on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-23.59" spread="26.928"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-24.79" spread="28.431"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-30.36" spread="28.697"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-34.00" spread="29.552"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Assessment Value</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-30.98" spread="30.484"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>40 mg Adalimumab Every Other Week</title>
          <description>Induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MeDRA 10.1">anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atroventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title vocab=", MedDRA 10.1">Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>GI haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>GI motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>ileal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>internal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>subileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>anatomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>anastomotic complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>anastomotic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>pulmonary emolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dyshidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Responsibility of preparation and maintenance of the single database, first publication, and, presentation of Study shall reside with Abbott. No independent manuscript may be submitted for publication until first manuscript has been accepted for publication or twelve (12) months after completion of the Study at all sites, which ever occurs first.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Subjects who failed prior infliximab therapy were eligible to enter study after minimum 8 week wash-out since last dose. Includes subjects who previously used infliximab &amp; never responded or responded &amp; developed intolerance/lost efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Information Specialist</name_or_title>
      <organization>Abbott Laboratories</organization>
      <phone>Phone: (800) 633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
